Literature DB >> 31299272

Generation of expandable human pluripotent stem cell-derived hepatocyte-like liver organoids.

Seon Ju Mun1, Jae-Sung Ryu2, Mi-Ok Lee2, Ye Seul Son1, Soo Jin Oh3, Hyun-Soo Cho1, Mi-Young Son1, Dae-Soo Kim4, Su Jung Kim3, Hyun Ju Yoo3, Ho-Joon Lee2, Janghwan Kim1, Cho-Rok Jung1, Kyung-Sook Chung5, Myung Jin Son6.   

Abstract

BACKGROUND & AIMS: The development of hepatic models capable of long-term expansion with competent liver functionality is technically challenging in a personalized setting. Stem cell-based organoid technologies can provide an alternative source of patient-derived primary hepatocytes. However, self-renewing and functionally competent human pluripotent stem cell (PSC)-derived hepatic organoids have not been developed.
METHODS: We developed a novel method to efficiently and reproducibly generate functionally mature human hepatic organoids derived from PSCs, including human embryonic stem cells and induced PSCs. The maturity of the organoids was validated by a detailed transcriptome analysis and functional performance assays. The organoids were applied to screening platforms for the prediction of toxicity and the evaluation of drugs that target hepatic steatosis through real-time monitoring of cellular bioenergetics and high-content analyses.
RESULTS: Our organoids were morphologically indistinguishable from adult liver tissue-derived epithelial organoids and exhibited self-renewal. With further maturation, their molecular features approximated those of liver tissue, although these features were lacking in 2D differentiated hepatocytes. Our organoids preserved mature liver properties, including serum protein production, drug metabolism and detoxifying functions, active mitochondrial bioenergetics, and regenerative and inflammatory responses. The organoids exhibited significant toxic responses to clinically relevant concentrations of drugs that had been withdrawn from the market due to hepatotoxicity and recapitulated human disease phenotypes such as hepatic steatosis.
CONCLUSIONS: Our organoids exhibit self-renewal (expandable and further able to differentiate) while maintaining their mature hepatic characteristics over long-term culture. These organoids may provide a versatile and valuable platform for physiologically and pathologically relevant hepatic models in the context of personalized medicine. LAY
SUMMARY: A functionally mature, human cell-based liver model exhibiting human responses in toxicity prediction and drug evaluation is urgently needed for pre-clinical drug development. Here, we develop a novel human pluripotent stem cell-derived hepatocyte-like liver organoid that is critically advanced in terms of its generation method, functional performance, and application technologies. Our organoids can contribute to the better understanding of liver development and regeneration, and provide insights for metabolic studies and disease modeling, as well as toxicity assessments and drug screening for personalized medicine.
Copyright © 2019 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Disease modeling; Drug toxicity; Hepatocytes; Liver; Organoids; Pluripotent stem cells

Mesh:

Substances:

Year:  2019        PMID: 31299272     DOI: 10.1016/j.jhep.2019.06.030

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  53 in total

Review 1.  Current status of hepatocyte-like cell therapy from stem cells.

Authors:  Yu Saito; Tetsuya Ikemoto; Yuji Morine; Mitsuo Shimada
Journal:  Surg Today       Date:  2020-08-04       Impact factor: 2.549

2.  Differentiation of Human Parthenogenetic Embryonic Stem Cells into Functional Hepatocyte-like Cells.

Authors:  Rui Liang; Zhiqiang Wang; Xiangyang Kong; Xiaoxiao Xiao; Tianxing Chen; Hui Yang; Ying Li; Xingqi Zhao
Journal:  Organogenesis       Date:  2020-11-25       Impact factor: 2.500

3.  Generation of multi-cellular human liver organoids from pluripotent stem cells.

Authors:  Wendy L Thompson; Takanori Takebe
Journal:  Methods Cell Biol       Date:  2020-05-22       Impact factor: 1.441

Review 4.  Advances in liver organoids: model systems for liver disease.

Authors:  Jaeseo Lee; Seon Ju Mun; Yongbo Shin; Seonbhin Lee; Myung Jin Son
Journal:  Arch Pharm Res       Date:  2022-06-04       Impact factor: 4.946

Review 5.  A potential ex vivo infection model of human induced pluripotent stem cell-3D organoids beyond coronavirus disease 2019.

Authors:  Hang Zhou; Li-Ping Liu; Mei Fang; Yu-Mei Li; Yun-Wen Zheng
Journal:  Histol Histopathol       Date:  2020-04-27       Impact factor: 2.303

Review 6.  Human liver model systems in a dish.

Authors:  Wendy L Thompson; Takanori Takebe
Journal:  Dev Growth Differ       Date:  2021-02-02       Impact factor: 2.053

7.  Establishment of human fetal hepatocyte organoids and CRISPR-Cas9-based gene knockin and knockout in organoid cultures from human liver.

Authors:  Delilah Hendriks; Benedetta Artegiani; Huili Hu; Susana Chuva de Sousa Lopes; Hans Clevers
Journal:  Nat Protoc       Date:  2020-11-27       Impact factor: 13.491

Review 8.  Convergence of human pluripotent stem cell, organoid, and genome editing technologies.

Authors:  Lin Wang; Zhaohui Ye; Yoon-Young Jang
Journal:  Exp Biol Med (Maywood)       Date:  2021-01-19

9.  Integrated Isogenic Human Induced Pluripotent Stem Cell-Based Liver and Heart Microphysiological Systems Predict Unsafe Drug-Drug Interaction.

Authors:  Felipe T Lee-Montiel; Alexander Laemmle; Verena Charwat; Laure Dumont; Caleb S Lee; Nathaniel Huebsch; Hideaki Okochi; Matthew J Hancock; Brian Siemons; Steven C Boggess; Ishan Goswami; Evan W Miller; Holger Willenbring; Kevin E Healy
Journal:  Front Pharmacol       Date:  2021-05-07       Impact factor: 5.810

Review 10.  The Combination of Cell Cultured Technology and In Silico Model to Inform the Drug Development.

Authors:  Zhengying Zhou; Jinwei Zhu; Muhan Jiang; Lan Sang; Kun Hao; Hua He
Journal:  Pharmaceutics       Date:  2021-05-12       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.